Form 4: Rapport Therapeutics CSO Sells Shares Under Pre-Arranged Trading Plan

Rapport Therapeutics, Inc.'s Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $93,522 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported a sale of 8,500 shares of common stock.
• The transaction occurred on June 16, 2025.
• The shares were sold at a weighted average price of $11.0026 per share, with prices ranging from $10.67 to $11.34.
• The total value of the shares sold was approximately $93,522.10 (8,500 shares * $11.0026/share).
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following this transaction, Mr. Bredt beneficially owns 443,642 shares of Rapport Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It's a routine, expected transaction.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary transaction rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-planned nature.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider stock sales.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock sale.

Stakeholder Impact

• Shareholders: May observe the sale as a routine liquidity event for an executive, especially given the 10b5-1 plan, but could also interpret it as a minor signal regarding insider confidence, though this is less likely for a pre-planned sale of this size.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Sale, David Bredt, Chief Scientific Officer, 10b5-1 Plan, Beneficial Ownership